Literature DB >> 23303487

Bidirectional regulation of intravenous general anesthetic actions by α3-containing γ-aminobutyric acid A receptors.

Carolin J Straub1, Hew Mun Lau, Rosanna Parlato, Guenther Schuetz, Jean-Marc Fritschy, Uwe Rudolph.   

Abstract

BACKGROUND: γ-aminobutyric acid A (GABAA) receptors mediate the actions of several intravenous general anesthetics. However, the contribution of α3-containing GABAA receptors to the action of these drugs is unknown.
METHODS: The authors compared anesthetic endpoints (hypnosis, immobility, hypothermia) in response to various intravenous anesthetics in mice lacking the α3 subunit of the GABAA receptor (α3 knockout) and in wild-type mice. Furthermore, the authors generated and analyzed conditional mutant mice expressing the GABAA receptor α3 subunit exclusively in noradrenergic neurons.
RESULTS: α3 knockout mice displayed decreased hypnotic and hypothermic responses to etomidate and midazolam, but an increased response to pentobarbital. The hypnotic response to ketamine was unaltered, whereas the hypothermic response was increased. In contrast, the hypnotic but not the hypothermic response to medetomidine was increased. The combination of ketamine/xylazine displayed increased hypnotic, immobilizing, and hypothermic effects in α3 knockout mice. Mice expressing the α3 subunit exclusively in noradrenergic neurons were generated to assess whether the lack of α3 subunits on noradrenergic neurons may be responsible for this effect. In these mice, the increases of the hypnotic and immobilizing actions induced by ketamine/xylazine were largely absent, whereas the increase in the hypothermic action was still present.
CONCLUSION: α3-containing GABAA receptors bidirectionally regulate essential anesthetic actions: they mediate anesthetic actions of etomidate and midazolam, known to selectively act at GABAA receptors, and they negatively constrain anesthetic actions of compounds with targets partly or exclusively distinct from GABAA receptors such as medetomidine, ketamine, and pentobarbital. Furthermore, our results indicate that α3-containing GABAA receptors on noradrenergic neurons may contribute to this constraint.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23303487      PMCID: PMC3951843          DOI: 10.1097/ALN.0b013e3182800d76

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  40 in total

1.  Genetic background differences between FVB and C57BL/6 mice affect hypnotic susceptibility to pentobarbital, ketamine and nitrous oxide, but not isoflurane.

Authors:  Y Sato; N Seo; E Kobayashi
Journal:  Acta Anaesthesiol Scand       Date:  2006-05       Impact factor: 2.105

Review 2.  Noradrenergic afferents and receptors in the medial preoptic area: neuroanatomical and neurochemical links between the regulation of sleep and body temperature.

Authors:  Velayudhan Mohan Kumar; Ramalingam Vetrivelan; Hruda Nanda Mallick
Journal:  Neurochem Int       Date:  2007-02-27       Impact factor: 3.921

3.  Immunofluorescence in brain sections: simultaneous detection of presynaptic and postsynaptic proteins in identified neurons.

Authors:  Edith M Schneider Gasser; Carolin J Straub; Patrizia Panzanelli; Oliver Weinmann; Marco Sassoè-Pognetto; Jean-Marc Fritschy
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

4.  Normal sleep homeostasis and lack of epilepsy phenotype in GABA A receptor alpha3 subunit-knockout mice.

Authors:  R Winsky-Sommerer; A Knapman; D E Fedele; C M Schofield; V V Vyazovskiy; U Rudolph; J R Huguenard; J-M Fritschy; I Tobler
Journal:  Neuroscience       Date:  2008-04-11       Impact factor: 3.590

Review 5.  General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal.

Authors:  Nicholas P Franks
Journal:  Nat Rev Neurosci       Date:  2008-05       Impact factor: 34.870

6.  Specific ablation of the transcription factor CREB in sympathetic neurons surprisingly protects against developmentally regulated apoptosis.

Authors:  Rosanna Parlato; Christiane Otto; Yvonne Begus; Stephanie Stotz; Günther Schütz
Journal:  Development       Date:  2007-03-21       Impact factor: 6.868

7.  Alpha5GABAA receptors mediate the amnestic but not sedative-hypnotic effects of the general anesthetic etomidate.

Authors:  Victor Y Cheng; Loren J Martin; Erin M Elliott; John H Kim; Howard T J Mount; Franco A Taverna; John C Roder; John F Macdonald; Amit Bhambri; Neil Collinson; Keith A Wafford; Beverley A Orser
Journal:  J Neurosci       Date:  2006-04-05       Impact factor: 6.167

8.  Identification of a molecular target mediating the general anesthetic actions of pentobarbital.

Authors:  Anja Zeller; Margarete Arras; Rachel Jurd; Uwe Rudolph
Journal:  Mol Pharmacol       Date:  2006-12-12       Impact factor: 4.436

Review 9.  GABA(A) receptor subtypes underlying general anesthesia.

Authors:  Robert P Bonin; Beverley A Orser
Journal:  Pharmacol Biochem Behav       Date:  2008-01-16       Impact factor: 3.533

10.  Reorganization of GABAergic circuits maintains GABAA receptor-mediated transmission onto CA1 interneurons in alpha1-subunit-null mice.

Authors:  Edith M Schneider Gasser; Venceslas Duveau; George A Prenosil; Jean-Marc Fritschy
Journal:  Eur J Neurosci       Date:  2007-06       Impact factor: 3.386

View more
  2 in total

1.  SB-205384 is a positive allosteric modulator of recombinant GABAA receptors containing rat α3, α5, or α6 subunit subtypes coexpressed with β3 and γ2 subunits.

Authors:  Laura S Heidelberg; James W Warren; Janet L Fisher
Journal:  J Pharmacol Exp Ther       Date:  2013-07-31       Impact factor: 4.030

2.  Itch suppression in mice and dogs by modulation of spinal α2 and α3GABAA receptors.

Authors:  William T Ralvenius; Elena Neumann; Martina Pagani; Mario A Acuña; Hendrik Wildner; Dietmar Benke; Nina Fischer; Ana Rostaher; Simon Schwager; Michael Detmar; Katrin Frauenknecht; Adriano Aguzzi; Jed Lee Hubbs; Uwe Rudolph; Claude Favrot; Hanns Ulrich Zeilhofer
Journal:  Nat Commun       Date:  2018-08-13       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.